inpefa (sotagliflozin)：FDA Update

FDA Update

2023年6月5日—forsotagliflozin(Inpefa),thefirstdualSGLT1andSGLT2inhibitorforthetreatmentofheartfailure(HF),includingHFwithpreserved ...。其他文章還包含有：「Inpefa(sotagliflozin)dosing,indications」、「INPEFATM(sotagliflozin)tablets」、「INPEFA®(Sotagliflozin)ReceivesPreferredFormulary...」、「NowApproved」、「Once」、「SCOREDTrial」、「Sotagliflozin(Inpefa)forheartfailure」、「Sotagliflozinfor...

查看更多離開網站

Provide From Google

Inpefa (sotagliflozin) dosing, indications

https://reference.medscape.com

Medscape - Heart failure dosing for Inpefa (sotagliflozin), frequency-based adverse effects, comprehensive interactions, contraindications, ...

Provide From Google

INPEFATM (sotagliflozin) tablets

https://www.accessdata.fda.gov

Resume INPEFA when the patient is clinically stable and has resumed oral intake [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)]. 3. DOSAGE ...

Provide From Google

INPEFA® (Sotagliflozin) Receives Preferred Formulary ...

https://finance.yahoo.com

Discovered using Lexicon's unique approach to gene science, INPEFA (sotagliflozin) is an oral inhibitor of two proteins responsible for glucose ...

Provide From Google

Now Approved

https://www.inpefahcp.com

INPEFA™ is an inhibitor of SGLT2 and SGLT1 for patients with heart failure or patients with comorbidities and other cardiovascular risk factors.

Provide From Google

Once

https://www.uspharmacist.com

Inpefa is classified as a dual inhibitor of both sodium-glucose cotransporter type 2 (SGLT2) and type 1 (SGLT1). Inhibiting SGLT2 diminishes ...

Provide From Google

SCORED Trial

https://www.inpefahcp.com

INPEFA ™ is indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with: heart ...

Provide From Google